Partial
Mostly Aligned
Patient Risk:
Low
Summary
Some claims about Inrebic’s indication and dose modifications are supported by the provided label sections, but several broad “SPC”/document-definition claims and “exact wording” claims are not supported by the supplied FDA label excerpts.
Category Scores
Accurate Statements
Inrebic (fedratinib) is approved for specific indications.
Supported by label section 1 INDICATIONS AND USAGE.
The SPC contains the recommended dose and how to start or adjust it.
Partially supported by label sections 2 DOSAGE AND ADMINISTRATION and 2.6 Dose Modifications for Adverse Reactions (dose modification guidance is present).
The SPC contains contraindications.
Supported by label section 4 CONTRAINDICATIONS (provided as 'None').
The SPC contains monitoring requirements and dose modifications for adverse effects.
Supported by label sections 2.6 Dose Modifications for Adverse Reactions, 5.3 Gastrointestinal Toxicity, 5.4 Hepatic Toxicity, and WARNING: ENCEPHALOPATHY INCLUDING WERNICKE'S.
Unsupported Statements
Inrebic is the brand name for fedratinib.
The provided label excerpts do not include a statement explicitly equating Inrebic with fedratinib as a brand name.
“SPC” usually refers to the Summary of Product Characteristics.
No 'SPC' term definition is present in the provided FDA label excerpts.
The Summary of Product Characteristics (SPC) is the official document that describes a medicine’s approved use, dosing, contraindications, warnings, and key safety information.
This is a general document-definition claim not supported by the provided label excerpts.
The SPC contains the exact indication wording.
The provided excerpts show indication text, but there is no basis in the supplied label content to verify the claim about 'exact indication wording' being contained in an 'SPC.'
The SPC contains interaction and metabolism information.
The label excerpts provided include 'Drug Interactions' (7 DRUG INTERACTIONS), but no metabolism-specific content is provided in the available excerpts to support 'metabolism information.'
Contradictions
Important Omissions
The claim set does not provide/verify the presence, or absence, of a separate FDA boxed warning section beyond the provided 'WARNING: ENCEPHALOPATHY INCLUDING WERNICKE'S' excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are largely about document terminology (SPC) rather than specific dosing/safety instructions. One statement about 'exact indication wording' is unsupported, and 'metabolism information' is only partially supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several broad, label-context document-definition claims and the 'exact indication wording' and 'metabolism information' claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what is directly evidenced by the provided label sections (e.g., indication text exists in 1; dose modifications in 2.6; contraindications in 4; Wernicke’s/thiamine warning and monitoring in the provided warnings and toxicity sections). Remove or qualify SPC/‘official document’ terminology and avoid metabolism-specific assertions unless metabolism content from the label is provided.